Jubilant Pharmova Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks

The Jubilant Pharmova share price target for 2026 stands at Rs 912 as per the latest analyst forecast, implying 29 percent upside from the current market price of Rs 705. Investors tracking the Jubilant Pharmova share price target 2026 need to understand the full picture including growth catalysts, FY27 earnings timeline, key risks, and the bull vs bear case scenarios. This article covers every dimension of the Jubilant Pharmova share price target thesis updated April 2026.

Click Here to Get Free Investment Predictions on Univest

Track live Jubilant Pharmova price, FII or DII flows and analyst targets on the Univest Screener.

Jubilant Pharmova Company Overview

Tap to Access Best Research on Univest

Jubilant Pharmova (NSE: JUBLPHARMA) is a listed company in India’s Pharma CDMO sector with a market capitalisation of Rs 11267 crore. At CMP Rs 705 against a 52 week range of Rs 565 to Rs 840, the stock currently offers meaningful upside to the analyst price forecast of Rs 912. For more share price target analysis, visit Univest Blogs.

Parameter	Value
NSE Ticker	JUBLPHARMA
Sector	Pharma CDMO
CMP April 2026	Rs 705
52 Week High	Rs 840
52 Week Low	Rs 565
Market Cap	Rs 11267 crore
Trailing P/E	32x
12M Analyst Price Forecast	Rs 912
Bull Case Target	Rs 1094
Bear Case Target	Rs 535

Why Analysts Set the Jubilant Pharmova Share Price Target at Rs 912 for 2026

FY27 Earnings Delivery and Revenue Acceleration

FY27 is the key year where analysts expect Jubilant Pharmova to deliver meaningful PAT growth. This is the primary variable that bridges the gap between the current CMP of Rs 705 and the Jubilant Pharmova share price target 2026 of Rs 912. Analysts project 15 to 20 percent PAT growth in FY27. Track Q4 results live on the Univest Screener.

Sustained domestic demand from rising incomes

Sustained domestic demand from rising incomes is a key growth driver that analysts highlight in supporting the Jubilant Pharmova share price target of Rs 912. The Pharma CDMO sector is expanding at 12 to 18 percent annually, and Jubilant Pharmova is well-positioned to capture a rising share. Discover top Pharma CDMO stocks on the Univest Screener.

Global supply chain realignment favouring India

Global supply chain realignment favouring India provides an additional lever that can help Jubilant Pharmova exceed analyst projections and potentially push the stock toward the bull case target of Rs 1094. Compare Jubilant Pharmova with sector peers on the Univest Screener.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s rate cut cycle that commenced in 2026 reduces Jubilant Pharmova’s borrowing costs and stimulates end-market demand, supporting the Jubilant Pharmova share price target 2026 of Rs 912.

Union Budget 2026-27 Policy Support

Budget 2026-27 capex continuity and PLI scheme extensions create a constructive backdrop for Jubilant Pharmova’s Pharma CDMO business, directly supporting the Jubilant Pharmova share price target 2026 bull case of Rs 1094.

Bull Case, Base Case and Bear Case for Jubilant Pharmova Share Price Target

Scenario	Target	Key Assumption
Bull Case	Rs 1094	FY27 revenue growth exceeds 25 percent, margin expansion of 200 bps, sector re-rating
Base Case Forecast	Rs 912	FY27 revenue growth of 15 to 18 percent, stable margins, current P/E sustained
Bear Case	Rs 535	Revenue growth disappoints below 10 percent, margin pressure, valuation de-rating

For live tracking of Jubilant Pharmova analyst price targets and ratings, use the Univest Screener.

Key Risks to the Jubilant Pharmova Share Price Target

Earnings Miss Risk

If Jubilant Pharmova reports quarterly earnings below expectations, the Jubilant Pharmova share price target will likely face downward revision. Watch Q4 FY26 results closely on Univest Screener.

Macro and Global Headwinds

The US 26 percent reciprocal tariff announcement of April 2026 has created global macro uncertainty that adds near-term risk to the Jubilant Pharmova share price target 2026 timeline.

Sector-Specific Risks

Regulatory changes, input cost volatility, and competitive intensity in the Pharma CDMO space could pressure margins and delay realisation of the Jubilant Pharmova share price target of Rs 912.

FII Outflows

Continued FII selling in Indian equities could suppress the valuation multiples needed for Jubilant Pharmova to reach its analyst price forecast of Rs 912 within the 12 month horizon.

Jubilant Pharmova Financial Snapshot FY25 to FY27

Metric	FY25 Actual	FY26 Estimate	FY27 Estimate
Revenue (Rs Cr)	Refer NSE filing	Refer NSE filing	Refer NSE/BSE filing
EBITDA Margin	Refer NSE filing	Refer NSE filing	Expected expansion
PAT (Rs Cr)	Refer NSE filing	Refer NSE filing	15 to 20 percent growth
Market Cap	Rs 11267 crore	Higher at 52W peak	Tracks price movement
P/E Ratio	32x	Current level	Target implies re-rating
52 Week High / Low	Rs 840 / Rs 565

If you want to track Jubilant Pharmova financial metrics, analyst ratings and peer comparisons in real time, check the Univest Screener for live data.

Technical Outlook for Jubilant Pharmova Share Price

Jubilant Pharmova is trading at Rs 705, currently attempting to build a base above its 52 week low of Rs 565. The stock needs to reclaim its 200 day moving average to confirm a meaningful recovery trend. The Jubilant Pharmova share price target of Rs 912 set by analysts assumes fundamental delivery over the next 12 months rather than near-term price action. Download the Univest iOS App or Univest Android App to track Jubilant Pharmova live price and set alerts.

Conclusion

The Jubilant Pharmova share price target 2026 of Rs 912 reflects analyst conviction on FY27 earnings delivery, structural sector tailwinds, and the favourable domestic macro environment. The bull case of Rs 1094 is achievable if the company executes above expectations. Investors should monitor quarterly earnings, FII ownership trends and management commentary closely. For real-time tracking and research, use the Univest Screener.

This article is for informational and educational purposes only and is not investment advice. Univest is SEBI registered (INH000013776). Please consult a SEBI registered financial advisor before making any investment decision.

Frequently Asked Questions

What is the Jubilant Pharmova share price target for 2026?

The Jubilant Pharmova share price target for 2026 is Rs 912 as per the analyst price forecast, implying 29 percent upside from the current price of Rs 705. The bull case target is Rs 1094 and the bear case is Rs 535.

Is Jubilant Pharmova a good buy at Rs 705?

At Rs 705, Jubilant Pharmova trades at a trailing P/E of 32x and offers potential upside to the analyst price forecast of Rs 912. Whether it is a good buy depends on your investment horizon and risk appetite. Always consult a SEBI registered financial advisor.

What is the 52 week high and low of Jubilant Pharmova?

The 52 week high of Jubilant Pharmova is Rs 840 and the 52 week low is Rs 565. The current CMP of Rs 705 positions the stock at a meaningful discount to its peak, which is factored into the analyst Jubilant Pharmova share price target 2026.

What sector does Jubilant Pharmova belong to?

Jubilant Pharmova belongs to India’s Pharma CDMO sector and trades on NSE with the ticker JUBLPHARMA. Track the entire Pharma CDMO sector on the Univest Screener.

What is the bull case for Jubilant Pharmova share price?

The bull case for Jubilant Pharmova share price is Rs 1094, which assumes revenue growth exceeding 25 percent in FY27, margin expansion of 200 basis points, and a positive re-rating of the Pharma CDMO sector. This scenario requires strong execution and supportive macro conditions.

What are the key risks to the Jubilant Pharmova share price target?

Key risks include earnings miss in upcoming quarters, continued FII selling, regulatory headwinds in the Pharma CDMO sector, raw material cost volatility, and global macro uncertainty driven by the US tariff environment. These risks could push the stock toward the bear case of Rs 535.

Recent Article

United Breweries Q4 Results FY26: PAT Rs 102 Crore on Strong Kingfisher Beer Summer Season Volumes

Ambuja Cement Share Price Target 2026: Analyst Consensus, Growth Catalysts and Key Risks

Voltamp Transformers Q4 Results FY26: PAT Rs 48 Crore on Industrial Transformer Demand from Core Sectors

Marico Q4 Results FY26: PAT Rs 391 Crore, Revenue Rs 3333 Crore Up 22 Percent, Dividend Up 30 Percent

Raymond Realty Q4 Results FY26: PAT Rs 161 Crore on Strong Thane Residential Project Sales